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Arrhythmogenic right ventricular dysplasia (ARVD)
is a kind of cardiomyopathy characterized by
fibro-fatty replacement of the right ventricular
(RV) myocardium. It may lead to RV dilatation
and predispose to ventricular tachyarrhythmia
originating from the RV. Patients with ARVD may
present with palpitations, dizzy spells, syncopal
attacks or even sudden cardiac death.
ARVD was first described in 1982 when Marcus
et al noticed a group of patients with RV dysplasia.1
These patients presented with ventricular tachy-
cardia, supraventricular arrhythmias, right-heart
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failure or asymptomatic cardiomegaly. In these
patients, the diagnosis was confirmed by either
biopsy or autopsy. Due to the broad spectrum of
clinical manifestations, the Task Force of the
European Society of Cardiology and International
Society and Federation of Cardiology proposed
diagnostic criteria in 1994,2 encompassing struc-
tural, functional and electrical aspects, and also
integrating the histology and inheritance pattern.
The pathogenesis of ARVD is not yet com-
pletely understood, but a genetic factor is known
to be involved. ARVD is inherited with an auto-
somal dominant pattern in some families. Link-
age analysis studies have identified at least 11
loci for ARVD and some of the causal genes have
been identified. Among these, the causal genes of
ARVD 8–11 are desmoplakin (DSP), plakophilin-2
(PKP2), desmoglein-2 (DSG2) and desmocollin-2
(DSC2) and they all encode major desmosomal
component proteins. It is therefore postulated that
disruption of the normal desmosome function
plays an important role in the pathogenesis of
ARVD.
In the present study, we reported the clinical
presentations, cardiac manifestations and desmo-
some gene mutations in ARVD patients in Taiwan.
Most studies on ARVD have been performed in
Western countries, and the clinical presentation
and incidence of desmosome gene mutations 
remain unknown in Asian countries. This study
was performed to determine possible ethnic or
geographical differences.
Methods
Study patients
We included five consecutive patients with ARVD
who visited the National Taiwan University Hos-
pital between 1997 and 2007. In addition to rou-
tine history-taking, physical examinations and
laboratory tests, the results of electrophysiologic
studies, cardiac magnetic resonance imaging (MRI)
and signal averaged electrocardiograms (ECG) were
collected. The patients were followed-up at ar-
rhythmic clinics at 3-month intervals. Implantable
cardioverter defibrillator (ICD) checks were per-
formed at 6-month intervals and immediately 
if the need for cardioversion therapy was sensed
by the patients. The prescribing of antiarrhythmic
agents was at the doctors’ discretion.
Genomic DNA isolation
Genomic DNA was extracted from five ARVD
probands and another 100 healthy controls who
came to our hospital for routine health check-ups.
Informed consent was obtained from all partici-
pating individuals. Peripheral blood samples were
collected after informed consent. Genomic DNA
was extracted from leukocytes using a modified
proteinase K method (Qiagen, Valencia, CA, USA).
Polymerase chain reaction (PCR)
A PCR protocol was set up to amplify the 24 exons
of DSP, 14 exons of PKP2, 15 exons of DSG2,
and 16 exons of DSC2. The base sequences of the
primer pairs as well as the annealing temperature
are listed in Table 1. The primers were designed
to cover the entire coding regions as well as the
nearby intron regions (100 base pair). PCR was
performed in thin-walled PCR tubes in a total
volume of 25 μL containing 100 ng of genomic
DNA, 0.12 μM of each primer, 100 μM dNTPs, 0.5
units of AmpliTaq Gold (PE Applied Biosystems,
Foster City, CA, USA), and 2.5 μL of GeneAmp
10× buffer II (10mM tris-HCl, pH 8.3, 50mM KCl),
in 2 mM MgCl2 as provided by the manufacturer.
Amplification was performed in a multiblock
system thermocycler (ThermoHybaid, Ashford,
UK). PCR amplifications were performed with an
initial denaturation step at 95°C for 10 minutes,
followed by 35 cycles consisting of denaturation
at 94°C for 30 seconds, primer annealing at 55°C
for 30 seconds and an elongation step at 72°C
for 1 minute unless otherwise specified in the
Electronic Supplementary Material (S1). The final
extension step was 72°C for 10 minutes. The
primers were designed based on the sequence
data in GenBank (accession number NM 004415
for DSP, NM 004572 for PKP2, NM 001943 for
DSG2, NM 004949 for DSC2). Multiple primer
pairs were used for large exons.
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Table 1. Base sequence of the primer pairs
Exon Forward primer Backward primer Ta
Desmoplakin (DSP)
1 ggtagcgagcagcgacctc aaaacctttccaccttcggg 65
2 agggtctcacaggagtggtt tctgttctgaaaaagcgtgtct 62
3 tggttcatgaatctccgtctgt gggaacatttgtgctgcctt 62
4 ttaagtcctggggtaaagaaaa ggaggaaaatcctgcaaacag 55
5 gcattagccatttgggaacc ttccccatttaagaagtgggatt 62
6 gggatctgaggccagtatctga atcgatgaacaggtgcctcc 62
7 tggtcagtgaatgcacaagg agaccaatcattccccgaga 62
8 aacagcgtgattctttggca ccaacccctggtgtagggta 62
9 agctttcatgcaggctcacc gcactcaaaatcaatgaagagg 62
10 atagtttcccgctgccacat aaatgcttgcttggctctgg 65
11 tgccgacgaatttgtgattt ttgttccatagctgctgatttc 62
12 tcagcttcatttgaggggaaa ggcaaggcatcgtgtgtcta 62
13 ggtttttgtgcagtggtgtga aggagggctgagctgacttg 65
14 cccatctagtgggtggcatt ccagttttatgcaaactccctt 58
15 gaaattcaaaggaagaagg tacagggtaaccaggcaaa 50
16 gtattaaaacagcatattgtac aagaagcttgagaaaagga 50
17 gctttgacgttgttccctt actgaaacccaataatcct 50
18 gcatacaatgggagaaggg tgaacaaccaaaaggggag 50
19 tcaagtgaatttctgggtga aagccttcacaaaatgggtt 62
20 tgctcatctcctaagctgtaac cgctttacaacaaatcagca 62
21 tagacgtgcagcccaatgat aagacaggcaggagacaggg 62
22 taggggaaacagcctggaga cagcgtattggagcatggaa 62
23.1 gaatgcacattggtctggga cacattgccttgctttctgc 62
23.2 taccaggcagagtgttccca ctccttgatggtggtcttcg 62
23.3 aggcacccggaagagagaat gcctcctcctgaaactcagc 62
23.4 actgaagcaggtcatgcagc ccagctgctgtttcctctga 62
23.5 tcacccgagaaaacaggagc aaccgcgtgatatcctggtc 62
23.6 gcaaacagtagtgcgacgga tgctcattcctcaagtgagctt 62
23.7 cggaacctgaggctggagta aaagaacagcagggcacaca 65
23.8 gagcaggcatccattgtta ctgtccgcttcgcttcgtc 62
24.1 caagctcacagtgtatccaggg tgcttggagtctttcgatctca 62
24.2 ggaagactcaatattcccgca aagcagatgctccagcgata 62
24.3 gaaggtgacagcaatgcagc ctgaagcaatctgggcttcc 62
24.4 ttgatgatccattttcaggca cagcttgaaccctggaggaa 62
24.5 ccttccaaggaatcagacaacc cgaataccgtggccctttt 65
24.6 cagaacgagctgtcactggg tgctcacacagttctttgaagg 62
24.7 cctcaggaagcgtagagtgg gtcaaagatggctgcaatgg 65
24.8 ttagcagctcccgacatgaa ttcggtgcttatcctcccat 62
24.9 cataggcttcgagggtgtga gtggcgtcaaagcttcctct 62
24.10 ggatgccataaatcgctcca gacgcactgcatccaagtgta 65
Plakophilin-2 (PKP2)
1 gtccagaggcaggcgagcag gcgggataggaggaggtg 55
2 gttcttggccttcattac cactagggttacattctttg 55
3.1 gggtaatagtcccagagtaatt aaacggtgtcgctaacag 55
3.2 tgccaccgagatatgctc gctgggagtcagtgaaagt 55
4 ggctgaatctgtgcctgtt ccaaagtgctgggaatat 55
5 acagatactgccttatagcc ccatcaatcatttgctcc 55
6 aagtctgccacatttgct tctcctgcctcagtctcc 55
(Contd.)
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Table 1. Continued
Exon Forward primer Backward primer Ta
7 agtcatagccctggagtt aagaaccaaaggcagaat 55
8 ccaaacacctggaagaag tgggattacaggcgtgag 55
9 ttttctagccatactcattg ctccctttctcattcttt 55
10 atttctggtctcctggtt tcttccctcactgtttca 55
11 gtggaggttgtggtgagc catctttgtgaacgggag 55
12 ctgggcaacagagcaaga gaccgcacattcacaacc 55
13,14 tgggctgggtagtagaaa tgggattacaggcgtgag 55
Desmoglein-2 (DSG2)
1 ccagggaggagccgagtg gattttccgaagccccaggt 62
2 agatttctcctcgggcact tgcactgaatacccctggat 62
3 gcctcataggaaatacgaagca ccggaatgggaaagagaatc 62
4 ggcttttggctaagatcaaatc gcatccaaagcgtaacctgt 62
5 ttcttgatcgagaagaaacacca aagcaatggcatgtaaagtcc 62
6 cccattcacgcttatgtcct tggacagcacatccctaaaa 62
7,8 tctacaactcccgaggcttttct ttttaagtgttcagggctcaaa 62
9.1 tgctgctatatttcctgtgcat tccaattatttggcctttgc 62
9.2 cctacacccattcccatcaa ggtgaaaattccccctcatc 62
10 gagaggggcttttaggatgg tcaatggtttctgatgttggaa 62
11 ttagtaccttctccactccaaa ggttcaggacctcatttcat 62
12 gcaatgaaagaacatttgtgga gcactcagattcccaaaagc 62
13 gacaagtccaggaagggacat cacttccctaggccccttta 62
14.1 ctggcctcagtggaaatagc gcaggcttctgtgttcttcc 62
14.2 tcatttctgccagtggatca tcttcgttcagtgcaacagc 62
14.3 gatggaaggtgggaagaaca cccccaccaccaatacataa 62
14.4 tgaccactgaaaccacgaag gggtcccatttctctttcct 62
15.1 tttccctgatggttccttgt gcggtcatctagctctcctt 62
15.2 cggcctcttacactgaggaa actgggaagctactgccaga 62
15.3 tcgctgaatgcttctattgg ctagaagccattgggtcagg 62
15.4 tctggcagtagcttcccagt gctggagcatacaccctctc 62
15.5 cacctcttcctgacccaatg gaagatgctgagtgccttcc 62
15.6 ccttggtagatcagccttatgc tgctatgcttggtaactctggtgga 62
15.7 acggtgtctggagctgga ggaagcagagacagtgtggtc 62
15.8 gccacaaactgacccagagt aaaaggcacctaagcagcag 62
Desmocollin-2 (DSC2)
1 agcagcgggcccagactgcgct gttttcctctgcaccctaggcg 55
2 gcctttttatgtgtatatcat ttcctttttatggctgtgtag 55
3 cacgtgcatacattactgttaa gtaatgttgattacgtctgaag 55
4 gtcattgtttaatgtttgagaa ataatggtaagagatggaaact 55
5 atagatgaaagctctgctgaa aaatggccaagcatcatcatt 55
6 tgaatttgaagcatacctcat tgtatgaattgaaacacagtt 55
7 ataaagggaacatagaacatgt gagttatacaggtactattgaa 55
8 ggagtgtaaagtaagatttcaa cagagatgtgcatattaaacaa 55
9 gtgctagggtttcaaatcatg ctttccattaaattctagcatgc 55
10 gcattgccaaatattaaatga gctaaattataataacgtaac 55
11 gcagtggcataaggtacttacc aacagagtgcatgtatccagc 55
12 tcagtgcatacttttgtggtga agtatcgcagacatcctgatgt 55
13 agaagaaatcagtgacattgta cttgaaagttactttaaagggt 55
14 tgtgtgtattaaccattgtaca tacgcattataagcgaattcat 55
15 ggcattatccgcttgatgttgttc caattagtagaattagtagattc 55
16,17 gctatactgaatttatagtgtgat taaaagtcataaagccactggctt 55
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DNA sequencing
Amplicons were purified by solid-phase extrac-
tion and were sequenced with the PE Applied
Biosystems Taq DyeDeoxy terminator cycle se-
quencing kit (PE Applied Biosystems) according
to the manufacturer’s instructions. Sequencing re-
actions were separated on a PE Applied Biosystems
373A/3100 sequencer. The sequencing results
were compared with the sequence in GenBank
(accession number NM 004415 for DSP, NM
004572 for PKP2, NM 001943 for DSG2, NM
004949 for DSC2). When a base variation was
found, a de novo PCR was performed and DNA
sequencing from the opposite direction was per-
formed to confirm the base variation. The adeno-
sine of the start codon (ATG) was numbered as
the first nucleotide when expressing genetic vari-
ations. If a possible mutation was identified, the
presence of the mutation was examined in 100
normal individuals.
Results
Clinical characteristics
The mean age at diagnosis was 53 ± 16 years, and
there were two men and three women (Table 2).
All five patients were sent to the emergency room
(ER) with the presentation of palpitations, chest
tightness, general weakness or consciousness loss.
In the ER, monomorphic ventricular tachycardia
with an LBBB pattern was documented in all of
them. When 12-lead ECGs were performed during
sinus rhythm, three patients demonstrated local-
ized prolongation of the QRS complex over V1–3,
and of these, two patients had a typical Epsilon
wave (Figure 1). None of the patients had the
RBBB pattern, and four had T-wave inversion
over V1–3. The results of the cardiac MRI are
summarized in Table 3. Severe RV dilatation was
found in four of the patients and aneurysm for-
mation in one. Three had severe reduction of RV
ejection fraction (< 35%) and one had localized
hypokinesia. On the other hand, all patients
showed major RV structural or functional alter-
ation on cardiac MRI. None had a family history
of premature sudden cardiac death. None of these
patients received an endomyocardial biopsy. All
patients received ICD implantation after the 
diagnosis was confirmed.
Among the five patients, one showed pro-
gressive deterioration of left ventricular pumping
function 8 years later and was hospitalized repet-
itively. Finally, she died of refractory congestive
heart failure in the same year. Of the other four
patients, one had multiple arrhythmic events
within 1 month after implantation, and all events
were successfully terminated by antitachycardic
pacing. Mexiletine and an angiotensin-converting
enzyme inhibitor were prescribed for the frequent
attacks because she was hesitant about amio-
darone treatment due to the side effect of pho-
tosensitivity. The other two patients received
amiodarone for arrhythmia control, and no ICD
therapy was needed in the follow-up interval.
One of the patients did not take any medications
Table 2. Clinical characteristics of the study patients
No. Age (yr)/sex Presentation FH
12-lead ECG VT
SAECG ICDEpsilon V1–V3 QRS > V1–V3 LBBB
waves 110 ms inverted T pattern
1 28/F Palpitations − + + + + + +
2 52/F Collapse − + + + + N/A +
3 50/M Dyspnea, chest tightness − − + + + + +
4 65/M Palpitations, syncope − − − − + − −
5 68/F Weakness, syncope − − − + + N/A +
FH = family history; ECG = electrocardiography; VT = ventricular tachycardia; SAECG = signal averaged ECG; ICD = implantable cardioverter defibrillator;
N/A = not available.
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after implantation of ICD and there was no ICD
discharge during the follow-up period.
Genetic analysis on desmosome genes
We first performed base-by-base screening of the
four desmosome genes in the five probands. We
identified 21 variations (10 in DSP, 8 in DSG2, 
2 in PKP2, 1 in DSC2) in the desmosome genes
(Table 4). Twelve of the variations were single
nucleotide polymorphisms (SNPs) as there was
no amino acid alteration related to the variation.
For the nine variations with possible functional
alteration (3 in DSP, 5 in DSG2, 0 in PKP2, 1 in
DSC2), we examined the frequency in 100 normal
aVR
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V1
V2
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V5
V6
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II
III
I
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III
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RV
Figure 1. (A) Electrocardiogram from Patient 1. Epsilon waves (arrows) are present from V1 to V3. There are also 
inverted T waves from V1 to V3 and even V4. (B) Ventricular tachycardia with LBBB morphology was recorded during
the attack. (C) Cardiac magnetic resonance imaging shows severe dilatation of the right ventricle (RV) and reduction of
right ventricular ejection fraction with no left ventricular impairment.
Table 3. Magnetic resonance imaging findings in the right ventricle of the study patients
No.
Severe Mild
Severe dilatation Severe dysfunction Localized RV aneurysms Mild RV hypokinesia
1 + + − −
2 + N/A − −
3 + + − −
4 + + − −
5 − − + +
RV = right ventricle; N/A = not available.
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subjects. Among these, four were common SNPs
and five were unique to the ARVD patients and
therefore judged as mutations. Among the five
probands, three had a DSG2 gene mutation (60%)
and one had a DSP gene mutation (20%). One
patient had two mutations in the DSG2 gene
(Table 5). All the mutations were novel and were
not found in the chromosomes from 100 healthy
controls. For the four common SNPs, the allele
frequencies in patients and controls were 16.6%
and 20.5% for DSP 3923G>A, 25.0% and 24.0%
for DSP 4535A>G, 33.3% and 35.5% for DSG2
2318G>A and 8.3% and 7.0% for DSC2 2326A>G.
Among the five mutations, four were missense
mutations causing substitution of an amino acid.
All four variants were predicted to result in major
protein rearrangement due to a change in amino
acid charges. The other mutation was a splicing
mutation on the 3 splice donor site of exon 10.
When the consensus sequence of the splice junc-
tion is mutated, intron 10 will be included dur-
ing mRNA processing causing major changes of
the protein product. The DNA sequencing results
of the five mutations identified are shown in
Figure 2.
Discussion
Clinical characteristics
In the five patients with ARVD in Taiwan, the mean
age at diagnosis was higher (53 ± 16 years) than
Table 4. Variations in arrhythmogenic right ventricular dysplasia (ARVD)-related desmosome genes in 
five patients with ARVD
Type of variation Exon Nucleotide change Amino acid change
Desmoplakin (DSP)
SNP 1 1-1insA –
SNP 19 2631G>A Arg877Arg
SNP 20 2862C>T Cys954Cys
SNP 23 3923G>A Arg1308Gln
SNP 23 4535A>G Tyr1512Cys
SNP 24 7122C>T Thr2374Thr
SNP 24 7278T>C Tyr2426Tyr
Missense mutation 24 7516G>A Arg2339Gln
SNP 24 8472G>C Gly2824Gly
SNP 24 8655T>C Phe2885Phe
Desmoglein-2 (DSG2)
SNP 8 861C>T Asn287Asn
Missense mutation 8 988A>G Asn330Asp
Splicing mutation 10 1423+1G>T Splicing variant
Missense mutation 11 1592T>G Phe531Cys
Missense mutation 14 2137G>A Glu713Lys
SNP 14 2318G>A Arg773Lys
SNP 15 2505A>G Thr835Thr
SNP 15 3321T>C Val1107Val
Plakophilin-2 (PKP2)
SNP 3 819G>A Pro273Pro
SNP 12 2292G>A Gln764Gln
Desmocollin-2 (DSC2)
SNP 15 2326A>G Ile776Val
SNP = single nucleotide polymorphism.
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in previous reports from Italy (24.5 ± 14 years),3
Netherlands (35.2 years),4 and United Kingdom
(38 ± 17 years).5 Fung and Sanderson had stud-
ied the clinical profile of 11 Chinese patients in
Hong Kong and found that the mean age at diag-
nosis was 42.6 years, which was also higher than in
Western countries.6 Even after we adjusted the di-
agnostic age according to the first attack of cardiac
T T T TG G G G GC C C CA A A A A A AA
DSG2 2137G>A (Glu713Lys) in patient 1
T G
90 100
TG N A G AA A C C GT G T A T G GG
DSG2 988A>G (Asn330Asp) in patient 2
590580
A T G AT G A T AA C A AA G A T G T TT
DSG2 1423+1G>T (Mutant splice product) in patient 2
280270
C T T TC G C T CT T T TC A G C C A TG
DSG2 homozygous 1592T>G (Phe531Cys) in patient 3
250240
G A C TG G G T CT T G GA G A G C G TA
DSP 7516G>A (Arg2339Gln) in patient 4
150140
Figure 2. DNA sequencing results of the five mutations identified.
Table 5. Desmosome gene mutations identified in five patients with arrhythmogenic right ventricular dysplasia
No. Gene Exon Nucleotide change Amino acid change Type of mutation
1 DSG2 14 2137G>A Glu713Lys Missense
2 DSG2 8 988A>G Asn330Asp Missense
2 DSG2 10 1423+1G>T Splicing variant Splicing
3 DSG2 11 1592T>G Phe531Cys Missense
4 DSP 24 7516G>A Arg2339Gln Missense
arrhythmia, the mean age was still high (45.6
years). Due to some symptoms being nonspecific,
such as general weakness or chest tightness, the
precise time of the first attack might not be exact
and might delay the time of diagnosis. Also, most
of the series from Western countries were of 
patients detected by screening family members
of the index patients. This would have identified
asymptomatic patients who might have symptoms
later in their life. The predominant sex was also
diverse in the different series. In the above men-
tioned series, most had male predominance (75%
in Netherlands, 63.6% in Hong Kong) and the
series from Italy showed equal prevalence (48%
male), similar to our series (40% male). There
was no family history in any of the five patients.
However, the method for acquiring family his-
tory was only by questioning whether there was
any family member with heart disease, palpitation
attacks or unexplained sudden death, but not by
performing thorough cardiac examinations such
as ECG, signal-averaged ECG, ultrasound, MRI
or angiography. This could have underestimated
the incidence of familial involvement.
The prevalence of ECG abnormalities was high.
T-wave inversion over the right precordial leads
was present in 80% of the patients. The existence
of an epsilon wave was also higher (40%) than
previous research (9–28%).6,7 Whether this phe-
nomenon represented more severe impairment
of the conduction or just reflected diagnosis at 
a later stage of the disease course is unknown. 
It is also possible that an ECG abnormality was 
a clue leading to further examination and there-
fore led to the incidence of ECG abnormalities
being relatively high.
The incidence of RV structural and functional
abnormalities detected in the cardiac MRI was
also higher. Over half had severe RV dilatation
and contractile dysfunction. They also had de-
layed hyper-enhancement over focal areas of the
RV wall. Combined with the ECG results, we
found that even in patients with extensive RV
structural and functional alterations, the ECG
might not show a depolarization abnormality.
On the other hand, a change in repolarization is
more common and might occur early in the dis-
ease course, although it is less specific for the 
disease.
We also reported the clinical course of the pa-
tients. According to Hulot et al, the annual mor-
tality rate is 2.3%, and the causes of death were
progressive heart failure in 60% and sudden
death in 29% in the era before ICD was avail-
able.7 In the ICD era, we expected a lower sud-
den death mortality rate. In our study, one out of
five patients died of pumping failure 8 years after
the initial diagnosis. All the other patients sur-
vived and one experienced attacks of arrhythmias,
which was terminated by ICD therapy. The clini-
cal course was similar to that reported in Western
countries.
Desmosome gene mutations
In this study, we focused our gene analysis on
desmosome-related genes (DSP, PKP2, DSG2,
DSC2). The desmosomes are complex structures
located on the cell membrane responsible for 
the intercellular structural integrity, and all four
genes encode crucial components of the desmo-
somes. The desmogleins and desmocollins are
members of the cadherin family of cell adhesion
molecules. They are transmembrane proteins and
bind the intracellular cytoskeleton of intermedi-
ate filaments through the plasma membrane to
the cadherins on the adjacent cells. Desmoplakins
are the important linker proteins that anchor 
the intermediate filaments to the cytoplasmic
domain of the cadherins. Plakophilins are found
in cytoplasm and nuclei, and may be involved in
molecular recruitment and stabilization during
desmosome formation. Loss of one of the pro-
teins may impair the function of the desmosome
and damage the integrity of the cardiac myocytes
or reduce the resistance of the dynamic heart to
the shearing forces, which has been observed by
electron microscopy in endomyocardial biopsy
tissues.3
DSG mutation
After the DSG2 gene mutation was first identi-
fied in ARVD by Awad et al,8 the prevalence of
C.C. Yu, et al
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DSG2 gene mutations in ARVD patients has been
reported. The prevalence rate was around 10% 
in reports from North America,8 Italy,9 and the
United Kingdom.10 Basso et al reported a higher
prevalence of the DSG2 mutation of up to 19%
in Italy.3 However, the prevalence of DSG2 muta-
tion was even higher (60%) in the present study,
indicating an important role of the DSG2 muta-
tion in Taiwan. However, a large-scale survey is
needed to confirm this. In addition, all the muta-
tions identified in the present study were novel.
The five mutations reported by Awad et al in the
very first report were located in the positions of
the propeptide in two, and in the extracellular
domain, the extracellular anchor domain, and the
intracellular cadherin-typical sequence in the other
three. Except for one patient, all of the patients
had single heterozygous missense mutations, and
this finding attested to the hypothesis of domi-
nant inheritance with variable penetrance.8 In the
next two series from London and Italy, almost all
parts of the DSG protein had been reported to
have causative mutations associated with ARVD.
In our series, two of the three missense mutations,
Asn330Asp and Phe531Cys, were located in ex-
tracellular domains, and the other one, Glu713Lys,
was in the intracellular anchor domain. All the
mutations caused amino acid substitution and
could possibly influence the adhesive capacity of
desmosomes.
Mutation 1423+1G>T affected the splice donor
site of intron 10, which may cause inclusion of
intron 10 and alternatively activate a cryptic splice
donor site in intron 10 or exon 11 or lead to a
premature termination, resulting in major pro-
tein changes. Abnormal splicing causing amino
acid changes had been reported in both the
London and Italian groups. In the Italian study,
the 1881+1A>G mutation affected the splice ac-
ceptor site of intron 12 and activated an alterna-
tive cryptic splice site in exon 13. This aberrant
spliced mRNA coded for a truncated protein,
missing the cytoplasmic domain.9 The Caucasian
group reported a deletion of 12 nucleotides,
which disrupted the splice acceptor site of exon
8. According to the splice prediction computer
program, this mutant allele would result in dele-
tion of four amino acid residues in the extracel-
lular domain 3.10 No splice mutant had been
reported from North America.8 Further functional
studies are needed to evaluate the effect of this
splice mutation.
For patient three, a homozygous 1592T>G
(Phe531Cys) mutation was identified. This raises
the possibility that this could be a rare SNP.
However, 1592T>G was not found in 100 indi-
viduals (200 chromosomes). The phenylalanine
at the 531 position is highly conserved among
many species including dog, horse, rabbit, mouse,
rat and even fowl and zebrafish. This suggests
that Phe531Cys is a disease-related mutation.
DSP mutation
Mutation in DSP was first reported by Rampazzo
et al in one Italian ARVD family in 2002.11 This
family had a mutation (S299R) in exon 7 of DSP,
which modified a putative phosphorylation site
in the N-terminal domain, responsible for bind-
ing plakoglobin. Yang et al identified another
four variants (V30M, Q90R, W233X, R2834H) in
a Caucasian population from North America.12
They also demonstrated the crucial role of DSP
expression in cardiomyocytes for maintaining
cardiac tissue integrity. Nonsense DSP mutations
had been reported to cause striate pulmoplantar
keratoderma in heterozygotes.13 However, the
patient in our series and those in other reports
showed an absence of skin defects. It is possible
that the defect in DSP is compensated by other
desmosomal proteins in the skin. The prevalence
rate of the DSP gene mutation in our series was
similar (20%) to reports in Italy (14.3%) and in
North America (6.1%).
We did not found any mutations in the PKP2
and DSC2 genes despite the fact that the PKP2
mutation was common in Western reports. This
might be attributed to ethnic differences.
Among the five patients, patient four did not
meet the diagnostic criteria for AVRD, but one
missense mutation was found in the DSP gene
(7916G>A). This patient suffered from paroxys-
mal palpitations and ECG during palpitations
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revealed sustained ventricular tachycardia. The
ventricular tachycardia had left bundle branch
morphology indicating an origin in the right ven-
tricular. Subsequent cardiac MRI showed severe
dilatation and dysfunction of the right ventricle.
Therefore, it was very likely that this patient had
ARVD, and this exposed the insufficiency of cur-
rent diagnostic criteria proposed by the Task Force
of the European Society of Cardiology and Inter-
national Society and Federation of Cardiology in
1994. With more and more understanding of 
the genetic mutation associated with this disease,
genetic analysis should be considered, both in
helping to diagnose ARVD in index patients, but
also in genetic consultation among ARVD family
members.
Study limitations
There were several limitations in the present study.
This case series contained only five patients. The
estimated mutation rate might not be precise.
Although some of the mutations were not found
in 100 normal individuals (200 chromosomes),
we could not completely exclude the possibility
of a rare SNP. The lack of detailed cardiac evalua-
tion in family members potentially underestimated
the incidence of familial involvement.
Conclusion
In conclusion, Taiwanese patients with ARDV had
similar clinical presentations to those reported
in Western countries, but were of an older age 
at presentation and diagnosis. Among the five
patients with ARVD in Taiwan, 80% had gene
mutations in desmosome-related proteins, which
was a surprisingly high frequency. Due to the
limitation in the number of controls, rare SNPs
rather than true mutations could not be com-
pletely excluded. However, this study still strongly
suggests that ARVD is a desmosome-related dis-
ease. However, the complex pathogenetic mecha-
nisms from gene defects to clinical phenotypes are
not clear. Further in vivo and in vitro functional
studies are needed.
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